United States · Platforms & data · Benzinga
Helus Pharma Touts Positive Data for Depression Drug

Detailed summary
Helus Pharma Inc. (NASDAQ:HELP) reported topline results from its pivotal Phase 3 APPROACH trial, showing its novel serotonergic agonist HLP003 rapidly and durably reduced…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)




